Meeting
2023 ASCO Annual Meeting
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Authors
Jesus G. Berdeja
Sarah Cannon Research Institute, Nashville, TN
Jesus G. Berdeja , Thomas G. Martin , Adriana Rossi , James H. Essell , David Samuel DiCapua Siegel , Sham Mailankody , Neeraj Saini , Houston Holmes , Binod Dhakal , Cristina J. Gasparetto , Samir S. Parekh , Socorro Portella , Guy Ledergor , Ashley Hammad , Franco Davi , Justin Skoble , Elizabeth Garner , Steven Brian Kanner , Syed Rizvi , Sundar Jagannath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Clinical Trial Registration Number
NCT05722418
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8063)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8063
Abstract #
TPS8063
Poster Bd #
55a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
First Author: Naval Guastad Daver
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.
First Author: David Bing Zhen
Poster
2020 ASCO Virtual Scientific Program
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.
First Author: Aaron Rapoport
Poster
2018 ASCO Annual Meeting
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
First Author: Robert F. Cornell